INOVIQ Signs Sonic Healthcare USA Deal to Validate Ovarian Cancer Test
IIQ: $0.145 +7.41% · MC: $18M
INOVIQ has licensed Sonic Healthcare USA to transfer, optimise and validate its EXO-OC ovarian cancer blood test at a New York laboratory. Sonic has an option to pursue a US commercial licence, but has not committed to one; any deal depends on successful validation and further discussions. The agreement follows INOVIQ’s recently announced staged plan to advance the test towards US commercialisation, targeted for early 2028. Separately, newly appointed director Andrew Chapman disclosed relevant interests in approximately 9 million INOVIQ shares.

Comments